Special Issue

Bladder Cancer and Personalized Treatment

Message from the Guest Editors

The integration of various “omics” technologies for investigating the genetic and genomic make-up of bladder cancer has improved our understanding of the molecular tumor biology and continues to contribute to the development of more personalized treatment approaches. Different molecular subtypes have been identified in (non)muscle invasive bladder cancer; the presence of tumor heterogeneity has been identified as a source of treatment resistance, and molecular tumor make-up is now being evaluated in different clinical studies as a predictor of treatment response. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of science and showcase some of the latest findings in the field of bladder omics. The topics include studies that investigate molecular biomarkers of response to treatment and radiomics to improve staging in muscle-invasive bladder cancer.

Guest Editors

Dr. Tahlita C. M. Zuiverloon

Dr. Markus Eckstein

Dr. Astrid A.M. van der Veldt

Deadline for manuscript submissions

closed (15 March 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/78455

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI